ormp

  • Ecco la 60° Edizione del settimanale "Le opportunità di Borsa" dedicato ai consulenti finanziari ed esperti di borsa.

    Questa settimana abbiamo assistito a nuovi record assoluti in Europa e a Wall Street. Il tutto, dopo una ottava che ha visto il susseguirsi di riunioni di banche centrali. Lunedì la Bank of Japan (BoJ) ha alzato i tassi per la prima volta dal 2007, mettendo fine all’era del costo del denaro negativo e al controllo della curva dei rendimenti. Mercoledì la Federal Reserve (Fed) ha confermato i tassi nel range 5,25%-5,50%, mentre i “dots”, le proiezioni dei funzionari sul costo del denaro, indicano sempre tre tagli nel corso del 2024. Il Fomc ha anche discusso in merito ad un possibile rallentamento del ritmo di riduzione del portafoglio titoli. Ieri la Bank of England (BoE) ha lasciato i tassi di interesse invariati al 5,25%. Per continuare a leggere visita il link

axelvento

dCellVax
Registrato
21/12/04
Messaggi
16.246
Punti reazioni
419
questa azienda sviluppa un prodotto formidabile innovativo...

INSULINA ORALE!!!!!!!!!!!

insomma una scommessa da seguire con molta attenzione...
sono cominciate le prove di faseI
un piccolo gruppo di volontari in buona salute ingerira' oralmente
le capsule di insulina di ORAMED....
Le produzione delle capsule sono state prodotte da SWISS CAPS,
un nome una garanzia....

http://biz.yahoo.com/prnews/070508/aqtu099.html?.v=5

shosholoza,,,,,,
 
un bel graficoneeeeeeeee ragasuoli.....

grazie!!!!
 

Allegati

  • sc.png
    sc.png
    29,1 KB · Visite: 252
cottone tu che sei del campo.....

conosci farmaco similare che sostituisce la siringa.....(insiluna)

thanks,,,,
 
axelvento ha scritto:
cottone tu che sei del campo.....

conosci farmaco similare che sostituisce la siringa.....(insiluna)

thanks,,,,

onestamente sono a conoscenza solo di un nuovo tipo di insulina per via inalatoria (EXUBERA-Pfizer), che permetterebbe il rilascio del farmaco a livello polmonare..., molto efficace, facile da usare,ma con effetti collaterali importanti quali tosse, raucedine (quindi vietata a fumatori ) emicrania , vertigini....nonchè più costosa.

...che sappia io, da che mondo e mondo l'insulina orale non è utilizaabile perchè proprio non assimilabile a livello gastrico( per un problema di ingombro molecolare)...in un prossimo futuro, l'escamotage potrebbe arrivare sfruttando l'assimiliazione sub-linguale....
 
allora dalla tua conoscienza medica,
mi dici che con le capsule nn ha nessun effetto...positivo?..

quindi è una battaglia persa in partenza!
 
axelvento ha scritto:
allora dalla tua conoscienza medica,
mi dici che con le capsule nn ha nessun effetto...positivo?..

quindi è una battaglia persa in partenza!

le vie della biotecnologia sono infinite....quello che è certo è che, ad oggi, l'assorbimento gastrico è stato impossibile...anche perchè l'insulina è una proteine facilmente aggredibile dagli acidi gastrici.
...però ho sentito parlare di sperimentazioni fatte con formulazioni di insulina incapsulata in nanosfere fatte di chitosano, che riescono ad attraversare la barriera gastrica senza subire alterazioni, e di altre ancora con una speciale sostanza gelatinosa in grado di fare altrettanto...
 
thanks,,per le spiegazioni,,cott
resta il fatto che se questa azienda riesce a portare avanti la sua sperimentazioni
con successo...
il mondo della biotec nel campo dell'insulina cambia radicalmente...

solo il pensiero che con un capsula risolvono il problema e al quanto grandioso!!!!

In data 8 maggio la faseI sulle persone è cominciata! OK!
 
me la sono giocata allo speciale Nostradamus "ciofecone".... long
 
L'azienda encorium quotata al nasdaq ticker enco
aiuta ormp nello sviluppo del suo prodotto...

queste piccole realta' se non vengono giudate da aziende solide...
non fanno strada!!!
 
pensa axel che volevo aprire un 3d.
poi ho visto che c'era.

news

Press Release Source: Oramed Pharmaceuticals Inc.


Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
Wednesday June 4, 8:45 am ET


JERUSALEM, June 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB - News; http://www.oramed.com), a developer of oral delivery systems, announced today that it has been selected to display its abstract, entitled Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin in Healthy Subjects, at the upcoming 68th Annual American Diabetes Association's Scientific Sessions Conference in San Francisco, highlighting the successful results from its oral insulin trials on healthy volunteers.
ADVERTISEMENT


The abstract will also be printed in the Scientific Sessions Abstract Book, the June 2008 supplement to the journal Diabetes.

Oramed's technology will be included in an oral presentation by Prof. Dr. Lutz Heinemann, CEO of Profil Institute for Metabolic Research, "Pharmacokinetics and Pharmacodynamics of Alternate Insulin Delivery Systems," on Saturday, June 7, 2008 from 4 pm to 6 pm.

"The selection of Oramed as one of the companies to exhibit at Scientific Sessions is a great opportunity that allows us to present our data from human trials to the leading scientists in the diabetes field from all over the world," said Nadav Kidron, Oramed CEO.

Oramed's abstract poster has been assigned presentation number 425-P Clinical Therapeutics/New Technology - Insulin Delivery Systems and is available for viewing throughout the conference. A representative of the company will be available to answer questions on Saturday, June 7 from 6-7PM and from 12-2PM on Monday, June 9 at San Francisco's Moscone Convention Center, Hall D.

For more information about the ADA and the upcoming conference, please visit http://professional.diabetes.org.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.


Company and Investor Relation Contacts:

Oramed Pharmaceuticals,
Eric Rosenberg,
Cell: +972-54-566-7713,
Office: +972-2-566-0001,
Email: eric@oramed.com .

Media Contacts:

Ruder Finn Israel for Oramed,
Matthew Krieger,
Cell: +972-54-467-6950,
Office: +972-2-589-2003,
Email: matthew@oramed.com .
 
26X28
EXTRA LONG!

Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
Wednesday March 25, 2009, 8:40 am EDT
Buzz up! Print JERUSALEM, March 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB - News; http://www.oramed.com), a developer of oral delivery systems, announced today that it has been selected to present the results from the study, entitled, "Open Label Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin Formulations in Subjects with Type 2 Diabetes (T2DM)" at the upcoming 69th Annual American Diabetes Association's Scientific Sessions Conference in New Orleans. The presentation will highlight the successful results from its oral insulin trials on type 2 diabetes patients completed in August 2008.

An abstract will also be printed in the Scientific Sessions Abstract Book, the June 2009 supplement to the journal Diabetes.

"Oramed is pleased to present this poster featuring the results from our phase 2A study of ORMD-0801 on type 2 diabetes patients and to share the information with our colleagues," said Nadav Kidron, Oramed CEO. "As we indicated at the completion of the study, the trial demonstrated that the oral insulin capsule had a good safety profile and was well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes."

Oramed's poster has been assigned presentation number 434-P Clinical Therapeutics/New Technology - Insulin Delivery Systems and is available for viewing throughout the conference. A representative of the company will be available to answer questions on Monday, June 8 from 12-2 PM at the Morial Convention Center.

For more information about the ADA and the upcoming conference, please visit http://professional.diabetes.org

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.


Company and Investor Relation Contacts:
Oramed Pharmaceuticals
Tara Horn
USA: +1-646-240-4193
Int'l:: +972-54-334-318
Office: +972-2-566-0001
Email: Tara@oramed.com
 
In the Pipeline: Oral Insulin

At this time in the United States, injection and infusion are the only methods available for taking insulin — but with various teams of researchers hard at work, and with noninjection forms of insulin already making their debut in certain countries, this situation may change in the future.

One product that is already available in Ecuador, India, and, on a very limited basis, Canada, is Oral-lyn, a formulation of Regular insulin that is sprayed into the mouth using a device similar to an asthma inhaler. The insulin is then absorbed through the mucous membranes lining the mouth. Oral-lyn begins lowering blood glucose levels in 5 minutes, peaks at 30 minutes, and stops working at 2 hours. Unlike inhaled insulins (such as the now-discontinued Exubera), Oral-lyn does not enter the lungs, both because of the design of the device used to take it, and because users are instructed not to inhale as they spray. Oral-lyn is currently in Phase III trials (trials to definitively assess the drug’s effectiveness) in the United States, Canada, Russia, Ukraine, Bulgaria, Romania, and Poland. It is being developed by Generex Biotechnology Corporation and is intended for use in people with Type 1 or Type 2 diabetes.

Oramed Pharmaceuticals, Inc., a company that creates oral methods for administering drugs typically given by injection, is also developing a noninjectable insulin. Presently in clinical trials to assess safety and effectiveness, this drug is a form of Regular insulin that is delivered in capsules that are swallowed. It will initially be intended for use in people with Type 2 diabetes. The capsules are specially formulated to avoid breakdown while in transit through the stomach. The insulin is absorbed in the intestine and then travels first to the liver.

According to the company, routing insulin to the liver first more closely mimics what normally happens in a person without diabetes than injecting or infusing insulin under the skin. The insulin signals the liver to store glucose and to refrain from releasing stored glucose to the bloodstream. This helps to lower the blood glucose level, relieving some of the burden on the pancreas to produce insulin, and therefore helping to preserve pancreatic function for longer.

Oramed Pharmaceuticals plans for the capsules to be available in select countries within the next few years and anticipates approval in the United States to follow several years later.

A set of researchers funded by the Indian government is also in the process of developing an insulin pill, which is scheduled to be studied in human trials within several months. This pill makes use of nanoparticles (extremely small particles) to deliver insulin to the bloodstream. Additional methods of insulin delivery now in the early stages of development are sublingual insulin, or insulin that is placed and absorbed under the tongue; inhalable insulin that is delivered through the lungs; and insulin suppositories to be absorbed through the lining of the rectum.

This blog entry was written by Diane Fennell, Associate Editor of Diabetes Self-Management magazine.
 
Indietro